PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents growing 3.56% while GNPX's declined -61.17%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Both GNPX and the company show zero Short-Term Investments Growth.
3.51%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half of GNPX's -50.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
11.32%
Higher PP&E (Net) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x GNPX's -4.04%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-18.41%
≥ 1.5x GNPX's -4.04%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half of GNPX's -36.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
65.90%
Less than half of GNPX's -38.99%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Similar yoy changes to GNPX's 144.34%. Walter Schloss finds parallel near-term liability trends.
114.06%
Above 1.5x GNPX's 13.75%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Above 1.5x GNPX's 13.75%. Michael Burry sees a potential leverage warning sign.
5.13%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
-6.19%
≥ 1.5x GNPX's -2.94%. David Dodd sees higher yoy retained profits than competitor.
-12.13%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to GNPX's zero value, indicating worse performance.
-4.02%
Below half GNPX's -64.03%. Michael Burry sees potential underperformance in building shareholder capital.
6.14%
Below half GNPX's -36.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both GNPX and the company show zero Total Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.